Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides

a technology of nucleosides and oligonucleotides, which is applied in the field of therapeutic use of oligonucleotides, can solve the problems of complicated picture of phosphorothioate oligonucleotides, the use of phosphorothioate oligonucleotides is more complex than originally expected, and achieves the effects of increasing the immunostimulatory effect, modulating the immune response, and reducing the immunostimulatory

Inactive Publication Date: 2011-03-10
IDERA PHARMA INC
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The invention provides methods for controlling the immune response caused by CpG dinucleotide-containing compounds. This is achieved by modifying the position of the CpG dinucleotide in the compound, either by adding an immunomodulatory moiety at a specific position or by introducing a modified linkage between the nucleosides. The invention also provides compounds with enhanced or reduced immunostimulatory effect, which can be used for either antisense or immunotherapy applications. Additionally, the invention provides methods for reducing gene expression using CpG-containing oligonucleotides with reduced immunostimulatory effect and inducing an immune response using CpG-containing compounds with greater immunostimulatory effect.

Problems solved by technology

Unfortunately, the use of phosphorothioate oligonucleotides has become more complex than originally expected.
This and other side effects have complicated the picture for phosphorothioate oligonucleotides.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides
  • Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides
  • Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides

Examples

Experimental program
Comparison scheme
Effect test

example 1

Modulation of Immunostimulatory Effect in Vitro

[0045]To study the impact of site of chemical modification of PS-oligos containing CpG motif, we chose two oligonucleotides. Oligo 1 and Oligo 2, each of which contains one CpG motif To evaluate the immunostimulatory activity of oligonucleotides in the present study, we will use a mouse spleen cell proliferation assay.

[0046]Mouse spleen lymphocytes are cultured with oligonucleotides at concentration of 0.1, 1, and 10 μg / mL. Oligo 1 and Oligo 2 will induce a dose dependent effect on cell proliferation. At 0.1 μg / mL, the proliferation index will increase. Substitution of 5′-flanking deoxynucleoside (Y1) of CpG motif of Oligo 1 or Oligo 2 with an immunomodulatory moiety according to the invention will result in complete suppression of cell proliferation at all concentrations used (FIG. 1). At 0.1 μg / mL, cell proliferation index will be similar to medium alone. Substitution of the 3′-flanking deoxynucleoside (X1) of CpG motif of Oligo 1 or ...

example 2

Effect of Immunomodulatory Moieties on Spleen Weight

[0047]After observing that above substitutions in modulates its immunostimulatory activity based on cell culture assay, we administer oligonucleotides listed in Table 1 intraperitonealy to mice and measure the spleen weights to confirm that the substitutions have similar effects in vivo. Administration of Oligo 1 or Oligo 2 will cause substantial increase in spleen weight. Substitution of a deoxynucleotide away from CpG motif towards 5′-end, positions Y6, Y5, Y4 or Y3 will cause progressive increase in spleen weights confirming an increase in their immunostimulatory activity. Substitutions of a deoxynucleoside toward the 3′-end of the CpG motif, in general, will cause less significant increase in spleen weight. Data are shown in FIGS. 2 and 3.

example 3

Synthesis of Oligonucleotides Containing Immunomodulatory Moieties

[0048]Oligonucleotides are synthesized on 1 micromolar scale using an automated DNA synthesizer (Expedite 8909, PerSeptive Biosystems, Foster City, Calif.). Standard deoxynucleoside phosphoramidites are obtained from PerSeptive Biosystems. 1′,2′-dideoxyribose phosphoramidite, propyl-1-phosphoramidite, 2′-deoxy-5-nitroindole-ribofuranosyl phosphoramidite, deoxyuridine phosphoramidite, dP phosphoramidite, d-2-aminopurine phosphoramidite, d-nebularine phosphoramidite and d-7-deazaguanine phosphoramidite are obtained from Glen Research (Sterling, Va.). Deoxyinosine phosphoramidite is obtained from ChemGenes (Ashland, Mass.). Normal coupling cycles are used for all phosphoramidites. Beaucage reagent is used as an oxidant to obtain phosphorothioate modification. After synthesis, oligonucleotides are deprotected by incubating CPG-bound oligonucleotide with concentrated ammonium hydroxide solution for 1.5-2 hours at room temp...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
weightaaaaaaaaaa
structureaaaaaaaaaa
Login to View More

Abstract

The invention provides methods for modulating the immune response caused by CpG dinucleotide-containing compounds. The methods according to the invention enables both decreasing the immunostimulatory effect for antisense applications, as well as increasing the immunostimulatory effect for immunotherapy applications.

Description

BACKGROUND OF THE INVENTIONRelated Applications[0001]This application is a continuation of U.S. patent application Ser. No. 11 / 274,043 filed on Nov. 15, 2005, which is a continuation of Ser. No. 09 / 845,623, filed on Apr. 30, 2001, which claims the benefit of U.S. Provisional Patent Application Ser. No. 60 / 201,578, filed on May 1, 2000. Each of the patent applications listed above is hereby incorporated by reference in its entirety.FIELD OF THE INVENTION[0002]The invention relates to the therapeutic use of oligonucleotides, both in the antisense approach, and as immunostimulatory agents.SUMMARY OF THE RELATED ART[0003]Oligonucleotides have become indispensable tools in modern molecular biology, being used in a wide variety of techniques, ranging from diagnostic probing methods to PCR to antisense inhibition of gene expression. This widespread use of oligonucleotides has led to an increasing demand for rapid, inexpensive and efficient methods for synthesizing oligonucleotides.[0004]Th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/00A61K39/395A61P37/00A61P35/00A61P29/00A61P37/08A61P31/00A61P17/00A61P11/00A61P11/06A61P37/04A61K31/7088A61K31/7115C12N15/09A61K31/712A61K31/7125A61K38/00A61K48/00A61P37/02A61P37/06C07H21/00C07H21/04C12N15/113C12N15/117
CPCA61K38/00Y10S514/885C07H21/00C12N15/113C12N15/117C12N2310/18C12N2310/315C12N2310/317C12N2310/3183C12N2310/33C12N2310/332C12N2310/334C12N2310/335C12N2310/336A61K2039/55561A61P11/00A61P11/06A61P17/00A61P29/00A61P31/00A61P35/00A61P37/00A61P37/02A61P37/04A61P37/06A61P37/08
Inventor AGRAWAL, SUDHIR
Owner IDERA PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com